Ibrutinib for relapsed/refractory mantle cell lymphoma: 7-year experience

被引：0
|
作者：
Grilo, I. T. [1 ]
Couto, M. E. [2 ]
Freitas, J. F. [3 ]
Pereira, D. P. [2 ]
Moreira, C. [2 ]
Chacim, S. [2 ]
Domingues, N. [2 ]
Santo, A. E. [2 ]
Martins, A. [2 ]
Viterbo, L. [2 ]
Oliveira, I. [2 ]
Moreira, I. [2 ]
Mariz, J. M. [2 ]
机构：
[1] Ctr Hosp Tras Os Montes & Alto Douro, Oncohematol Dept, EPE, Chaves, Portugal
[2] IPO Porto, Porto, Portugal
[3] IPO Porto, Hematooncol Dept, Porto, Portugal
来源：
ANNALS OF ONCOLOGY | 2019年 / 30卷
关键词：
D O I：
10.1093/annonc/mdz413.060
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
56P
引用
收藏
页数：1
相关论文
共 50 条
  • [1] Ibrutinib in refractory mantle cell lymphoma or relapsed data update
    Paillassa, Jerome
    [J]. HEMATOLOGIE, 2015, 21 (05): : 257 - 259
  • [2] IBRUTINIB EXPERIENCE IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA AND MANTLE CELL LYMPHOMA: SINGEL CENTER EXPERIENCE
    Uysal, A.
    Soyer, N. Akad
    Patir, P.
    Duran, M.
    Koseoglu, F. D.
    Sahin, F.
    Vural, F.
    Tombuloglu, M.
    Saydam, G.
    [J]. LEUKEMIA RESEARCH, 2016, 49 : S35 - S35
  • [3] Five year experience in ibrutinib therapy for relapsed and refractory mantle cell lymphoma in real world Russian clinical practice
    Vorobyev, Vladimir, I
    Gemdzhian, Eduard G.
    Fedorova, Liudmila, V
    Mikhailova, Natalia B.
    Ilyasov, Ridvan K.
    Kaleikina, Liliia P.
    Trubyakova, Olga S.
    Kaplanov, Kamil D.
    Melnichenko, Elena, V
    Martynova, Elena, V
    Yakovleva, Elena P.
    Li, Olga Yu
    Tarasenko, Elena, V
    Chumakova, Elena P.
    Bulieva, Natalia B.
    Nesterova, Ekaterina S.
    Margolin, Oleg, V
    Zherebtsova, Vera A.
    Butaev, Lev S.
    Ptushkin, Vadim V.
    [J]. TERAPEVTICHESKII ARKHIV, 2021, 93 (07): : 770 - 777
  • [4] Clinical outcomes for ibrutinib in relapsed or refractory mantle cell lymphoma in real-world experience
    Jeon, Young-Woo
    Yoon, Seugyun
    Min, Gi June
    Park, Sung-Soo
    Park, Silvia
    Yoon, Jae-Ho
    Lee, Sung-Eun
    Cho, Byung-Sik
    Eom, Ki-Seong
    Kim, Yoo-Jin
    Kim, Hee-Je
    Lee, Seok
    Min, Chang-Ki
    Lee, Jong Wook
    Cho, Seok-Goo
    [J]. CANCER MEDICINE, 2019, 8 (16): : 6860 - 6870
  • [5] A retrospective analysis of ibrutinib outcomes in relapsed or refractory mantle cell lymphoma
    Lee, Yong-Pyo
    Jung, Ye Ji
    Cho, Junhun
    Ko, Young Hyeh
    Kim, Won Seog
    Kim, Seok Jin
    Yoon, Sang Eun
    [J]. BLOOD RESEARCH, 2023, 58 (04) : 208 - 220
  • [6] Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma
    Wang, Michael L.
    Rule, Simon
    Martin, Peter
    Goy, Andre
    Auer, Rebecca
    Kahl, Brad S.
    Jurczak, Wojciech
    Advani, Ranjana H.
    Romaguera, Jorge E.
    Williams, Michael E.
    Barrientos, Jacqueline C.
    Chmielowska, Ewa
    Radford, John
    Stilgenbauer, Stephan
    Dreyling, Martin
    Jedrzejczak, Wieslaw Wiktor
    Johnson, Peter
    Spurgeon, Stephen E.
    Li, Lei
    Zhang, Liang
    Newberry, Kate
    Ou, Zhishuo
    Cheng, Nancy
    Fang, Bingliang
    McGreivy, Jesse
    Clow, Fong
    Buggy, Joseph J.
    Chang, Betty Y.
    Beaupre, Darrin M.
    Kunkel, Lori A.
    Blum, Kristie A.
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2013, 369 (06): : 507 - 516
  • [7] Ibrutinib and Ixazomib in Relapsed/Refractory Mantle Cell Lymphoma: Precog 0404
    Cohen, Jonathon B.
    Jegede, Opeyemi
    Portell, Craig A.
    Hamadani, Mehdi
    Diefenbach, Catherine S.
    David, Kevin A.
    Fletcher, Christopher D.
    Landsburg, Daniel J.
    Mantha, Suparna
    Kahl, Brad S.
    [J]. BLOOD, 2022, 140 : 6487 - 6488
  • [8] Efficacy and safety of ibrutinib in Japanese patients with relapsed or refractory mantle cell lymphoma
    Maruyama, Dai
    Nagai, Hirokazu
    Fukuhara, Noriko
    Kitano, Toshiyuki
    Ishikawa, Takayuki
    Shibayama, Hirohiko
    Choi, Ilseung
    Hatake, Kiyohiko
    Uchida, Toshiki
    Nishikori, Momoko
    Kinoshita, Tomohiro
    Matsuno, Yoshihiro
    Nishikawa, Tomoaki
    Takahara, Satoko
    Tobinai, Kensei
    [J]. CANCER SCIENCE, 2016, 107 (12) : 1785 - 1790
  • [9] SIMULATION MODEL OF IBRUTINIB IN TREATMENT OF RELAPSED OR REFRACTORY MANTLE CELL LYMPHOMA (MCL)
    Peng, S.
    Sorensen, S.
    Pan, F.
    Dorman, E.
    Sun, S.
    Van Sanden, S.
    Sengupta, N.
    Gaudig, M.
    [J]. VALUE IN HEALTH, 2014, 17 (07) : A620 - A620
  • [10] Australian experience with ibrutinib in patients with relapsed/refractory mantle cell lymphoma: a study from the Lymphoma and Related Diseases Registry
    Baggio, Diva
    Wellard, Cameron
    Chung, Eliza
    Talaulikar, Dipti
    Keane, Colm
    Opat, Stephen
    Giri, Pratyush
    Minson, Adrian
    Cheah, Chan Yoon
    Armytage, Tasman
    Lee, Denise
    Chong, Geoffrey
    Johnston, Anna
    Cochrane, Tara
    Waters, Neil
    Hamad, Nada
    Wood, Erica M.
    Hawkes, Eliza A.
    [J]. LEUKEMIA & LYMPHOMA, 2023, 64 (03) : 621 - 627
12345